search
Back to results

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome (SS)

Primary Purpose

Sjögren's Syndrome

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
VIB4920
Placebo
Sponsored by
Viela Bio (acquired by Horizon Therapeutics)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sjögren's Syndrome focused on measuring Sjögren's Syndrome, SS, VIB4920, MEDI4920

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosed with SS by meeting the 2016 American College of Rheumatology (ACR)/EULAR Classification Criteria.
  • Residual salivary gland function as defined by whole stimulated salivary flow > 0.1 mL/min (only for Population 2).
  • Have an ESSDAI score of >= 5 at screening; (not including the peripheral nervous system, central nervous system, and pulmonary domains) (only for Population 1).
  • Have an ESSPRI score of >= 5 at screening (only for Population 2).
  • Have an ESSDAI score of < 5 at screening (only for Population 2).
  • Positive for either anti-Ro autoantibodies or rheumatoid factor, or both at screening.
  • Male and female participants who agree to follow protocol defined contraceptive methods.
  • No active or untreated latent tuberculosis (TB).

Exclusion Criteria:

  • Medical history of confirmed deep venous thrombosis or arterial thromboembolism within 2 years of signing the informed consent form (ICF).
  • Risk factors for venous thromboembolism or arterial thrombosis, prothrombotic status.
  • Concomitant polymyositis or dermatomyositis or systemic sclerosis.
  • Active malignancy or history of malignancy, except in situ carcinoma of the cervix and cutaneous basal cell carcinoma.
  • Hepatitis B, hepatitis C, or human immunodeficiency virus infection.
  • More than one episode of herpes zoster and/or an opportunistic infection in the last 12 months.
  • Active viral, bacterial, or other infections or history of more than 2 infections requiring intravenous antibiotics within 12 months prior to signing the ICF.
  • Participants with corona virus disease 2019 (COVID-19) infection or who, in the judgment of the investigator, are at unacceptable risk of COVID-19 or its complications.
  • A documented positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) test within 2 weeks prior to randomization.
  • Received live (attenuated) vaccine within the 4 weeks prior to ICF signature.
  • Treated with any biologic B-cell-depleting therapy within 12 months or other B-cell targeting therapy < 3 months before randomization.
  • Injectable corticosteroids (including intraarticular) or treatment with > 10 mg/day dose oral prednisone or equivalent within 6 weeks prior to randomization (only for Population 1).
  • Treated with systemic corticosteroids for indications other than SS, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) for more than a total of 2 weeks within 24 weeks prior to screening visit (only for Population 1).
  • Received previous treatment with anti-CD40L compounds at any time before screening.
  • Pregnant or lactating or planning to get pregnant during the duration of the study.

Sites / Locations

  • Research Site
  • Research site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research site
  • Research Site
  • Research site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

VIB4920 Dose 1 in Population 1

Placebo in Population 1

VIB4920 Dose 1 in Population 2

Placebo in Population 2

Arm Description

Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.

Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.

Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.

Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.

Outcomes

Primary Outcome Measures

Change From Baseline in European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) at Day 169 in Population 1
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) at Day 169 in Population 2

Secondary Outcome Measures

Change From Baseline in ESSPRI at Day 169 in Population 1
Percentage of Participants achieving ESSDAI [3] and ESSDAI [4] response in Population 1
Percentage of Participants achieving ESSPRI response in Population 2
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Score at Day 169 in Populations 1 and 2
Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169 in Populations 1 and 2
Patient's Global Impression of Severity at Day 169 in Populations 1 and 2
Number of participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Populations 1 and 2
Number of participants With Adverse Events of Special Interest (AESIs) in Populations 1 and 2
Number of Participants With Abnormal Laboratory Parameters, Vital Signs, and Electrocardiograms (ECGs) Reported as TEAEs in Populations 1 and 2
Plasma Concentration of VIB4920
Percentage of Participants With Positive Antibody Titer to VIB4920 in Populations 1 and 2

Full Information

First Posted
October 2, 2019
Last Updated
May 28, 2023
Sponsor
Viela Bio (acquired by Horizon Therapeutics)
search

1. Study Identification

Unique Protocol Identification Number
NCT04129164
Brief Title
A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
Acronym
SS
Official Title
A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
October 16, 2019 (Actual)
Primary Completion Date
September 1, 2022 (Actual)
Study Completion Date
March 10, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Viela Bio (acquired by Horizon Therapeutics)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
Detailed Description
The study will enrol 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity defined by European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) >= 5; Population 2 will include participants with moderate to severe subjective symptoms defined by EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score >= 5 and residual stimulated salivary flow but with mild systemic disease activity defined by ESSDAI score < 5. This study will include 3 periods: screening (4 weeks), treatment period (40 Weeks) and follow-up period (12 weeks). In the treatment period, participants from each of the populations will be randomized at 1:1 ratio to receive intravenous (IV) dose of VIB4920 or placebo (Stage I). After completion of Stage I, participants randomized to VIB4920 in Stage I will receive placebo and participants randomized to placebo in Stage I will receive VIB4920 (Stage II). Participants who had study drug discontinuation will not be eligible for treatment during Stage II. All participants will be followed for at least 12 weeks after their last dose of study drug administration.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sjögren's Syndrome
Keywords
Sjögren's Syndrome, SS, VIB4920, MEDI4920

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
183 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VIB4920 Dose 1 in Population 1
Arm Type
Experimental
Arm Description
Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
Arm Title
Placebo in Population 1
Arm Type
Placebo Comparator
Arm Description
Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
Arm Title
VIB4920 Dose 1 in Population 2
Arm Type
Experimental
Arm Description
Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
Arm Title
Placebo in Population 2
Arm Type
Placebo Comparator
Arm Description
Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
Intervention Type
Drug
Intervention Name(s)
VIB4920
Other Intervention Name(s)
Dazodalibep
Intervention Description
Intravenous Dose 1.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Intravenous dose matched to VIB4920.
Primary Outcome Measure Information:
Title
Change From Baseline in European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) at Day 169 in Population 1
Time Frame
Baseline (Day 1) and Day 169
Title
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) at Day 169 in Population 2
Time Frame
Baseline (Day 1) and Day 169
Secondary Outcome Measure Information:
Title
Change From Baseline in ESSPRI at Day 169 in Population 1
Time Frame
Baseline (Day 1) and Day 169
Title
Percentage of Participants achieving ESSDAI [3] and ESSDAI [4] response in Population 1
Time Frame
Baseline (Day 1) to Day 169
Title
Percentage of Participants achieving ESSPRI response in Population 2
Time Frame
Baseline (Day 1) to Day 169
Title
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Score at Day 169 in Populations 1 and 2
Time Frame
Baseline (Day 1) and Day 169
Title
Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169 in Populations 1 and 2
Time Frame
Baseline (Day 1) and Day 169
Title
Patient's Global Impression of Severity at Day 169 in Populations 1 and 2
Time Frame
Day 169
Title
Number of participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Populations 1 and 2
Time Frame
From Baseline (Day 1) up to Day 365
Title
Number of participants With Adverse Events of Special Interest (AESIs) in Populations 1 and 2
Time Frame
From Baseline (Day 1) up to Day 365
Title
Number of Participants With Abnormal Laboratory Parameters, Vital Signs, and Electrocardiograms (ECGs) Reported as TEAEs in Populations 1 and 2
Time Frame
From Baseline (Day 1) up to Day 365
Title
Plasma Concentration of VIB4920
Time Frame
Day 1 to Day 365
Title
Percentage of Participants With Positive Antibody Titer to VIB4920 in Populations 1 and 2
Time Frame
Day 1 to Day 365

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed with SS by meeting the 2016 American College of Rheumatology (ACR)/EULAR Classification Criteria. Residual salivary gland function as defined by whole stimulated salivary flow > 0.1 mL/min (only for Population 2). Have an ESSDAI score of >= 5 at screening; (not including the peripheral nervous system, central nervous system, and pulmonary domains) (only for Population 1). Have an ESSPRI score of >= 5 at screening (only for Population 2). Have an ESSDAI score of < 5 at screening (only for Population 2). Positive for either anti-Ro autoantibodies or rheumatoid factor, or both at screening. Male and female participants who agree to follow protocol defined contraceptive methods. No active or untreated latent tuberculosis (TB). Exclusion Criteria: Medical history of confirmed deep venous thrombosis or arterial thromboembolism within 2 years of signing the informed consent form (ICF). Risk factors for venous thromboembolism or arterial thrombosis, prothrombotic status. Concomitant polymyositis or dermatomyositis or systemic sclerosis. Active malignancy or history of malignancy, except in situ carcinoma of the cervix and cutaneous basal cell carcinoma. Hepatitis B, hepatitis C, or human immunodeficiency virus infection. More than one episode of herpes zoster and/or an opportunistic infection in the last 12 months. Active viral, bacterial, or other infections or history of more than 2 infections requiring intravenous antibiotics within 12 months prior to signing the ICF. Participants with corona virus disease 2019 (COVID-19) infection or who, in the judgment of the investigator, are at unacceptable risk of COVID-19 or its complications. A documented positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) test within 2 weeks prior to randomization. Received live (attenuated) vaccine within the 4 weeks prior to ICF signature. Treated with any biologic B-cell-depleting therapy within 12 months or other B-cell targeting therapy < 3 months before randomization. Injectable corticosteroids (including intraarticular) or treatment with > 10 mg/day dose oral prednisone or equivalent within 6 weeks prior to randomization (only for Population 1). Treated with systemic corticosteroids for indications other than SS, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) for more than a total of 2 weeks within 24 weeks prior to screening visit (only for Population 1). Received previous treatment with anti-CD40L compounds at any time before screening. Pregnant or lactating or planning to get pregnant during the duration of the study.
Facility Information:
Facility Name
Research Site
City
Fullerton
State/Province
California
ZIP/Postal Code
92835
Country
United States
Facility Name
Research site
City
Upland
State/Province
California
ZIP/Postal Code
91786
Country
United States
Facility Name
Research Site
City
Lawrenceville
State/Province
Georgia
ZIP/Postal Code
30046
Country
United States
Facility Name
Research Site
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
Research Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224
Country
United States
Facility Name
Research Site
City
Wheaton
State/Province
Maryland
ZIP/Postal Code
20902
Country
United States
Facility Name
Research Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02111
Country
United States
Facility Name
Research Site
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Facility Name
Research Site
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Research Site
City
Salisbury
State/Province
North Carolina
ZIP/Postal Code
28144
Country
United States
Facility Name
Research Site
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Research site
City
Duncansville
State/Province
Pennsylvania
ZIP/Postal Code
16635
Country
United States
Facility Name
Research Site
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
Facility Name
Research site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77084
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77089
Country
United States
Facility Name
Research Site
City
Ciudad Autonoma de Buenos Aires
State/Province
Buenos Aires
ZIP/Postal Code
C1114AAH
Country
Argentina
Facility Name
Research Site
City
Bordeaux
Country
France
Facility Name
Research Site
City
Brest
Country
France
Facility Name
Research Site
City
Grenoble
Country
France
Facility Name
Research Site
City
Paris Cedex 13
Country
France
Facility Name
Research Site
City
Paris
Country
France
Facility Name
Research Site
City
Strasbourg
Country
France
Facility Name
Research Site
City
Budapest
ZIP/Postal Code
1097
Country
Hungary
Facility Name
Research Site
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Facility Name
Research Site
City
Gyula
ZIP/Postal Code
5700
Country
Hungary
Facility Name
Research Site
City
Secunderabad
State/Province
Andhra Pradesh
ZIP/Postal Code
5000003
Country
India
Facility Name
Research Site
City
Ahmedabad
State/Province
Gujarat
ZIP/Postal Code
380015
Country
India
Facility Name
Research Site
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560010
Country
India
Facility Name
Research Site
City
Pune
State/Province
Maharshtra
ZIP/Postal Code
411001
Country
India
Facility Name
Research Site
City
Pune
State/Province
Maharshtra
ZIP/Postal Code
411013
Country
India
Facility Name
Research Site
City
Bhubaneswar
State/Province
Odisha
ZIP/Postal Code
751005
Country
India
Facility Name
Research Site
City
Chennai
State/Province
Tamil Nadu
ZIP/Postal Code
600004
Country
India
Facility Name
Research Site
City
Milano
State/Province
Lambardia
ZIP/Postal Code
20122
Country
Italy
Facility Name
Research Site
City
Rome
State/Province
Lazio
ZIP/Postal Code
00161
Country
Italy
Facility Name
Research Site
City
Brescia
State/Province
Province Of Brescia
ZIP/Postal Code
25123
Country
Italy
Facility Name
Research Site
City
Perugia
State/Province
Umbria
ZIP/Postal Code
06129
Country
Italy
Facility Name
Research Site
City
Pisa
ZIP/Postal Code
56126
Country
Italy
Facility Name
Research Site
City
Udine
ZIP/Postal Code
33100
Country
Italy
Facility Name
Research Site
City
Suwon si
State/Province
Gyeonggi
ZIP/Postal Code
16499
Country
Korea, Republic of
Facility Name
Research Site
City
Incheon
State/Province
Republic Of Korea
ZIP/Postal Code
21565
Country
Korea, Republic of
Facility Name
Research Site
City
Incheon
State/Province
Republic Of Korea
ZIP/Postal Code
22332
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
State/Province
Republic Of Korea
ZIP/Postal Code
06591
Country
Korea, Republic of
Facility Name
Research Site
City
Saltillo
State/Province
Coahuila
ZIP/Postal Code
25000
Country
Mexico
Facility Name
Research Site
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44650
Country
Mexico
Facility Name
Research Site
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44690
Country
Mexico
Facility Name
Research Site
City
Ciudad de mexico
ZIP/Postal Code
06700
Country
Mexico
Facility Name
Research Site
City
Lima
State/Province
San Martin De Porres
ZIP/Postal Code
31
Country
Peru
Facility Name
Research Site
City
Lima
ZIP/Postal Code
1
Country
Peru
Facility Name
Research Site
City
Lima
ZIP/Postal Code
33
Country
Peru
Facility Name
Research Site
City
Elbląg
State/Province
Elblag
ZIP/Postal Code
82-300
Country
Poland
Facility Name
Research Site
City
Krakow
ZIP/Postal Code
30-363
Country
Poland
Facility Name
Research Site
City
Lublin
ZIP/Postal Code
20-412
Country
Poland
Facility Name
Research Site
City
Poznan
ZIP/Postal Code
60-693
Country
Poland
Facility Name
Research Site
City
Siedlce
ZIP/Postal Code
08-110
Country
Poland
Facility Name
Research Site
City
Szczecin
ZIP/Postal Code
71-252
Country
Poland
Facility Name
Research Site
City
Warszawa
ZIP/Postal Code
02-637
Country
Poland
Facility Name
Research Site
City
Warszawa
ZIP/Postal Code
02-691
Country
Poland
Facility Name
Research Site
City
Wrocław
ZIP/Postal Code
02-637
Country
Poland
Facility Name
Research Site
City
Kaohsiung
ZIP/Postal Code
81362
Country
Taiwan
Facility Name
Research Site
City
Taichung City
ZIP/Postal Code
40705
Country
Taiwan
Facility Name
Research Site
City
Newcastle Upon Tyne
ZIP/Postal Code
NE1 4LP
Country
United Kingdom
Facility Name
Research Site
City
Truro
ZIP/Postal Code
TR13LJ
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

We'll reach out to this number within 24 hrs